Journal of Pediatric Surgery
Volume 43, Issue 3 , Pages 451-460 , March 2008

Doxycycline sclerotherapy as primary treatment of head and neck lymphatic malformations in children

References 

  1. Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg. 2000;37(8):517–584
  2. Smith RJ. Lymphatic malformations. Lymphat Res Biol. 2004;2(1):25–31
  3. Giguere CM, Bauman NM, Sato Y, et al. Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Arch Otolaryngol Head Neck Surg. 2002;128(10):1137–1144
  4. Bloom DC, Perkins JA, Manning SC. Management of lymphatic malformations. Curr Opin Otolaryngol Head Neck Surg. 2004;12(6):500–504
  5. Penna KJ, Verveniotis SJ. Lymphangiomatous macroglossia. Medical and surgical treatment. N Y State Dent J. 1995;61(10):30–33
  6. Hancock BJ, St-Vil D, Luks FI, et al. Complications of lymphangiomas in children. J Pediatr Surg. 1992;27(2):220–224[discussion 224-6]
  7. Padwa BL, Hayward PG, Ferraro NF, Mulliken JB. Cervicofacial lymphatic malformation: clinical course, surgical intervention, and pathogenesis of skeletal hypertrophy. Plast Reconstr Surg. 1995;95(6):951–960
  8. Molitch HI, Unger EC, Witte CL, et al. Percutaneous sclerotherapy of lymphangiomas. Radiology. 1995;194(2):343–347
  9. Won JH, Kim BM, Kim CH, et al. Percutaneous sclerotherapy of lymphangiomas with acetic acid. J Vasc Interv Radiol. 2004;15(6):595–600
  10. Banieghbal B, Davies MR. Guidelines for the successful treatment of lymphangioma with OK-432. Eur J Pediatr Surg. 2003;13(2):103–107
  11. Marchi E, Teixeira LR, Vargas FS. Management of malignancy-associated pleural effusion: current and future treatment strategies. Am J Respir Med. 2003;2(3):261–273
  12. Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29(5):829–838
  13. Greinwald JH, Burke DK, Sato Y, et al. Treatment of lymphangiomas in children: an update of Picibanil (OK-432) sclerotherapy. Otolaryngol Head Neck Surg. 1999;121(4):381–387
  14. Luzzatto C, Midrio P, Tchaprassian Z, et al. Sclerosing treatment of lymphangiomas with OK-432. Arch Dis Child. 2000;82(4):316–318
  15. Smith RJ, Burke DK, Sato Y, et al. OK-432 therapy for lymphangiomas. Arch Otolaryngol Head Neck Surg. 1996;122(11):1195–1199
  16. Dubois J, Garel L, Abela A, et al. Lymphangiomas in children: percutaneous sclerotherapy with an alcoholic solution of zein. Radiology. 1997;204(3):651–654
  17. Emran MA, Dubois J, Laberge L, et al. Alcoholic solution of zein (Ethibloc) sclerotherapy for treatment of lymphangiomas in children. J Pediatr Surg. 2006;41(5):975–979
  18. Gericke KR. Doxycycline as a sclerosing agent. Ann Pharmacother. 1992;26(5):648–649
  19. Zaloznik AJ, Oswald SG, Langin M. Intrapleural tetracycline in malignant pleural effusions. A randomized study. Cancer. 1983;51(4):752–755
  20. Okada A, Kubota A, Fukuzawa M, et al. Injection of bleomycin as a primary therapy of cystic lymphangioma. J Pediatr Surg. 1992;27(4):440–443
  21. Orford J, Barker A, Thonell S, et al. Bleomycin therapy for cystic hygroma. J Pediatr Surg. 1995;30(9):1282–1287
  22. Fordham L, Chung C, Donnelly L. Imaging of congenital vascular and lymphatic anomalies of the head and neck. Neuroimaging Clin N Am. 2000;10:117–135

PII: S0022-3468(07)00818-4

doi: 10.1016/j.jpedsurg.2007.10.009

Journal of Pediatric Surgery
Volume 43, Issue 3 , Pages 451-460 , March 2008

Article Tools

* Image Usage & Resolution